Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Peringkat dalam Saham #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Harga Saham
$58.70
Terakhir disinkronkan: 2024-01-23
Kapitalisasi Pasar
$2.98B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Mirati Therapeutics, Inc. (MRTX)

Kategori

Riwayat pemecahan saham untuk Mirati Therapeutics, Inc. (MRTX)
Saham Mirati Therapeutics, Inc. (simbol: MRTX) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Aug 27, 2026.
Satu lembar saham MRTX yang dibeli sebelum Aug 27, 2026 sekarang setara dengan 0 lembar saham MRTX.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH